other_material
confidence high
sentiment negative
materiality 0.95
Plus Therapeutics stockholders approve 20x authorized share increase to 2B; massive dilution authorized
PLUS THERAPEUTICS, INC.
- Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.
- Stockholders approved issuance of up to 1.26B shares upon exercise of Series B Warrants with zero exercise price.
- Warrant exercise price reset to floor of $0.132; Series A/B could total ~1.68B shares if fully exercised.
- All proposals passed with >88% votes for; quorum of 8.2M shares out of 11.8M outstanding.
- Item 8.01 confirms massive potential equity dilution from prior private placement warrants.